In a preclinical study, T cells derived from human peripheral blood mononuclear cells were engineered to express TCR specific for the MAGE-A4 143–151 peptide (NYKRCFPVI) and adoptively transferred to immunodeficient NOG mice following inoculation with MAGE-A4-expressing human tumor cell lines. Here, MAGEA4 is linked to neoplasm.